sumatriptan succinate / Generic mfg. - LARVOL DELTA

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Remote Electrical Neuromodulation (REN) wearable reduces medication use for the treatment of chronic pain in migraine patients (PAINWeek 2026) - "Medication types included three categories that were presented to patients using commercial drug names: (1) over-the-counter (OTC; e.g. Advil, Excedrin, Tylenol), (2) first-line prescribed medications including oral triptans (e.g. Imitrex, Maxalt, Relpax) and oral medication for nausea (e.g. Zofran, Reglan, Compazine), (3) second-line prescribed medications including nasal/injectable triptans (e.g. Tosymara, Onzetra, Zembrace, Zoming) and branded new generation medications (Reyvow, Nurtec, and Ubrelvy). Data from 31,516 migraine patients who conducted 148,705 REN treatments were analyzed. Treatment-level analysis showed that 71.1% of the treatments were performed without the use of any prescribed medications (50.6% REN alone, 14.4% REN + OTC meds), while 28.9% were conducted in conjunction with first- or second-line prescribed medications. A patient-level analysis looked at a subset of 2,653 patients who performed at least 10 REN treatments each, in which they reported..."

Clinical • CNS Disorders • Migraine • Pain

Comparison table: Triptans. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Visual, vestibular, and ocular motor changes during nitroglycerin-triggered vestibular migraine. (PubMed, Headache) - "Quantitative slow phase velocity measures of nystagmus did not show a uniform group-level change during NTG provocation in VM, despite frequent subjective vestibular symptoms. VM episodes may reflect altered central sensory processing and vestibular hypersensitivity rather than changes in vestibulo-oculomotor output."

Journal • CNS Disorders • Immunology • Migraine • Ophthalmology • Pain • Retinal Disorders

Breaking the Collagen Barrier: Successful Treatment of Collagenous Gastritis With Oral Budesonide (ACG 2026) - "Medications included sumatriptan, ondansetron, dicyclomine, and magnesium oxide...Pantoprazole was continued, and a budesonide taper was initiated...Our case adds to the growing evidence for the use of steroids and PPI for the treatment of Collagenous gastritis. Figure: Stomach - Gross Finding: Nodular Gastritis Figure: Biopsy findings"

Barrett Esophagus • CNS Disorders • Colonic Polyps • Colorectal Cancer • Crohn's disease • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Migraine • Rare Diseases • Solid Tumor

Ischemic Colitis Reporting Across the Triptan Class: A Cross-Database Analysis With FDA Label Review (ACG 2026) - " We queried the FDA Adverse Event Reporting System (FAERS) and WHO VigiBase on 5/1/2026 for IC reports associated with sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, and frovatriptan... Sumatriptan had the highest absolute IC case volume (FAERS: 87 cases; VigiBase: 114 cases) consistent with its dominant overall reporting volume. Rizatriptan was the only agent with significantly elevated IC reporting proportions in both FAERS (1.76% vs 0.79%, p=0.0007) and VigiBase (0.55% vs 0.31%, p=0.009). Frovatriptan was elevated in FAERS only (4.48% vs 0.85%, p=0.020)."

Review • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Migraine

Validated LC-MS/MS method for ultra-trace determination of N-nitroso-desmethyl sumatriptan in sumatriptan succinate injection. (PubMed, J Pharm Biomed Anal) - "Analysis of commercial injection batches confirmed NNDS levels within acceptable limits. The validated method is suitable for routine quality control, stability assessment, and regulatory monitoring of nitrosamine impurities in pharmaceutical products."

Journal

Targeting Gi/o-coupled GPCRs to inhibit nociceptors: Insights from the serotonin receptor Htr1b and triptans. (PubMed, Cell Rep Med) - "Experiments focusing on the Gi/o-coupled serotonin receptor Htr1b, which is expressed in mouse and human CGRP+ DRG neurons, reveal that Htr1b/1d agonists, the triptans sumatriptan and zolmitriptan, attenuate CGRP+ neuron excitability in vitro and exhibit analgesia across several pain models, including neuropathic pain. Further testing identifies the GPCR Gpr19 as an additional promising target for treating pain. These findings establish a preclinical screening platform for identifying analgesic candidates and reveal nociceptor GPCRs that may be targeted to treat pain."

Journal • Neuralgia • Pain

Epidemiology, Safety of Dilation, and Medication-Associated Risk of Acute Angle-Closure Crisis in the United States. (PubMed, Am J Ophthalmol) - "AACC following pharmacologic dilation was rare and occurred predominantly among patients with anatomical risk factors, supporting the safety of dilation in routine clinical care. Medication-associated risk signals were observed across commonly prescribed drugs at the population level, including previously unreported associations, highlighting the importance of proactive ocular risk assessment and medication reconciliation in anatomically predisposed patients. Novel medication associations with calcium channel blockers, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation."

Journal • Glaucoma • Ophthalmology

Prediction of migraine treatment response with clinical and genetic data: A machine learning analysis of the HUNT study. (PubMed, Cephalalgia) - "We developed models that predicted treatment responses to amitriptyline, beta-blockers, candesartan and topiramate with modest accuracy. Incorporating genetic data did not enhance performance, although the limited sample size and the uncertain accuracy of cohort definition and treatment response assessment prevent firm conclusions."

Journal • CNS Disorders • Migraine • Pain • Preventive care

Unveiling the sumatriptan dose-relief relationship. (PubMed, Eur J Clin Pharmacol) - "The present correlation provides a relationship between the dose of sumatriptan and its effect for multiple routes of administration. The approach developed in this work could be adapted to other molecules to explore their dose-response relationships."

Journal • CNS Disorders • Migraine • Pain

Left Main Spontaneous Coronary Artery Dissection in a Young Woman With Migraine and Triptan Use. (PubMed, JACC Case Rep) - "SCAD may occur in patients with migraines even without traditional cardiovascular risk factors and especially after exposure to triptans."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Hematological Disorders • Ischemic stroke • Migraine • Pain • Psychiatry • Thrombosis

Real-World Utilization of Acute Treatments for Cluster Headache: Insights from the French National Open Health Data (EAN 2026) - " We extracted consumption data for the two validated attacks treatments for CH: 6 mg subcutaneous sumatriptan (SS) and oxygen therapy (OT)... Our findings highlight evolving treatment patterns and shifting sex ratio in the delivery of CH therapies in France. While no clear environmental drivers of treatment used were identified, the study underscores the value of open health data in monitoring prescribing trends and evaluation the economic impact of CH therapies."

Clinical • Real-world • Real-world evidence • Migraine

Comparative efficacy and safety of metoclopramide versus sumatriptan in acute management of migraine: A systematic review and meta-analysis (EAN 2026) - No abstract available

Retrospective data • Review • CNS Disorders • Migraine

PN6047 Demonstrates Broad Preclinical Efficacy in Headache Models as a Novel Delta-Opioid Receptor Agonist. (PubMed, bioRxiv) - "C57BL6/J mice were used to examine the effects of PN6047 in the following migraine models: chronic intermittent nitroglycerin (NTG)-induced migraine-associated pain, PTH, KCl-induced cortical spreading depression (CSD), and optogenetic evoked CSD in a freely behaving transgenic mice expressing ChR2-eYFP. In addition, we tested whether chronic PN6047 induced MOH and whether it could prevent the development of MOH induced by sumatriptan...Importantly, prolonged PN6047 treatment did not induce MOH or analgesic tolerance. Together, these data demonstrate that despite the distinct mechanisms underlying migraine and headache disorder, PN6047 exhibits robust efficacy without inducing MOH, and displays a favorable safety and tolerability profile."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Migraine • Neuralgia • Pain • Psychiatry

Esculetin attenuates migraine-like pain via CGRP suppression and meningeal mast cell modulation in rat models. (PubMed, J Zhejiang Univ Sci B) - "The systemic effects of esculetin at three distinct doses (5, 10, and 20 mg/kg) were tested in a nitroglycerin (NTG)-induced migraine model using in vivo experimental sets...Sumatriptan was used as a positive control in both sets of experiments...Our findings suggest that esculetin exhibits anti-nociceptive activities in experimental migraine conditions, alleviating trigeminovascular CGRP concentrations and the degranulation of meningeal mast cells. Esculetin may thus represent a therapeutic option for relieving migraine headaches, although further research is needed to confirm this."

Journal • Preclinical • CNS Disorders • Inflammation • Migraine • Oncology • Pain • FOS

A highly efficient method to differentiate CGRP-expressing peptidergic nociceptors from human induced pluripotent stem cells. (PubMed, Stem Cell Reports) - "Importantly, they were able to release CGRP basally and upon stimulation by inflammatory soup, which was inhibited upon the application of the 5-HT1B/1D/1F agonist, sumatriptan, a migraine prophylactic drug. We report the successful generation of a novel in vitro functional peptidergic nociceptor model which will allow investigation of disease mechanisms in pain and translational phenotypic drug screening for new effective pain therapies."

Journal • CNS Disorders • Inflammation • Migraine • Neuralgia • Pain • TRPV1

Efficacy of Elismetrep, a Novel, Selective, and Oral Blocker of the Migraine-associated Channel TRPM8, as a Monotherapy and in Combination with Gepants or Triptans in Preclinical Models (AHS 2026) - "Elismetrep, a TRPM8 migraine-associated channel blocker is effective both as a monotherapy and when administered in combination with either olcegepant or sumatriptan in a preclinical periorbital allodynia model relevant to migraine. TRPM8 is an ion channel expressed on a distinct set of trigeminal ganglion neurons and represents a mechanistically distinct target from those targeted by current therapeutics for migraine including CGRP receptor antagonists and serotonergic (5-HT)-based agents."

Combination therapy • Monotherapy • Preclinical • CNS Disorders • Migraine • Pain • ADCYAP1 • TRPM8

Targeting AVEN Liquid-Liquid Phase Separation in Colorectal Cancer: Insights From a Raddeanin A-Based Chemical Probe. (PubMed, Basic Clin Pharmacol Toxicol) - "Furthermore, we identified sumatriptan (SUM) as a potent inhibitor of AVEN IDRs, which demonstrated promising therapeutic efficacy in mouse models and clinical cohorts. Our study highlights the critical role of AVEN in regulating mitochondrial homeostasis via LLPS and suggests that targeting AVEN represents a promising therapeutic strategy for CRC."

Journal • Colorectal Cancer • Metabolic Disorders • Oncology • Solid Tumor

Behavioral and pharmacological characterization of the isosorbide dinitrate model of headache in male and female rats (AHS 2026) - "Pretreatment with morphine sulfate (mu opioid agonist), SNC80 (delta opioid agonist), sumatriptan (5-HT1B/1D agonist), olcegepant (CGRP receptor antagonist), and celecoxib (COX-2 inhibitor) all suppressed the development of transient ISDN-induced facial allodynia in a dose-dependent manner. The ISDN model produces reliable transient and persistent facial mechanical allodynia, and persistent allodynia is more pronounced in female rats compared to male rats. Reference analgesics that are clinically effective for the treatment of migraine are efficacious in the ISDN model, demonstrating translatable pharmacology. We are continuing to characterize the behavioral phenotype of this model by evaluating additional behavioral endpoints associated with migraine including photophobia and phonophobia."

Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Migraine • Pain

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

The association of acute medication utilization and clinician specialty in the treatment of pediatric chronic migraine: A cross-institutional electronic health record analysis (AHS 2026) - "Rizatriptan, sumatriptan, zolmitriptan, and almotriptan are approved for use in children, while gepants are not yet approved in children but may sometimes be used off-label. Among pediatric patients with chronic migraine, care through neurology was associated with significantly higher acute migraine medication utilization. Pediatric-only care was associated with lower rates of use, suggesting potential gaps in access or lower familiarity and comfort with migraine-specific treatments, leading to potential delays in optimal care. These findings highlight possible disparities in access to neurologists or other system-driven treatment gaps, rather than differences in clinical need for migraine-specific therapies."

Clinical • CNS Disorders • Migraine • Pain

The development of a just in time teaching module to rapidly and effectively educate health care providers on updated American Headache Society evidence for acute management of migraine in the emergency room (AHS 2026) - "Secondly, it reviews how Prochlorperazine IV and GONB could be offered to adults while hydromorphone IV should not. Potential treatments include ketorolac IV, metoclopramide IV, sumatriptan SC, and SONB. Chlorpromazine IV, dexamethasone IV, and valproate IV may be offered. In general, acetaminophen IV should not be offered, and additional evidence is needed for caffeine, granisetron, ibuprofen, ketamine, lidocaine and others... Many health care providers in the emergency room setting provide idiosyncratic and non-evidence based parenteral care. Our educational piece was developed in order to rapidly educate providers on essential aspects of recognizing migraine in the emergency room and what evidence based recommendations are suggested by the American Headache Society. Once the educational piece is accepted for inclusion in the app, it can be used to help standardize education and ensure a rapid, meaningful guide to care for acute treatment of migraine in the emergency..."

CNS Disorders • Migraine • Pain

Comparison of FDA approved intranasal acute migraine treatment adverse event profiles (AHS 2026) - "One Sentence Summary: STS101 (dihydroergotamine nasal powder) shows a low rate of local adverse events in its approved prescribing information as compared with other approved intranasal acute migraine treatments...Prescribing information dates reviewed were ATZUMI (April 2025), Migranal (September 2022), Trudhesa (May 2022), Zavzpret (August 2025), Imitrex nasal spray (December 2025), and Zomig nasal spray (May 2019)... Nasally administered products for the acute treatment of migraine are generally well tolerated. STS101 shows a favorable adverse event profile in long term prn use as compared with other FDA-approved intranasal acute migraine treatments. Most commonly reported adverse events (≥5% and occurring more frequently than placebo) as listed in the U.S. prescribing information for FDA-approved intranasal acute migraine treatments."

Adverse events • CNS Disorders • Migraine • Pain

Atogepant for refractory migraine in MELAS syndrome: A case report (AHS 2026) - "One Sentence Summary: A patient with MELAS syndrome and refractory migraines failed conventional treatments like topiramate and onabotulinumtoxinA...Within the first month, headache days decreased to 8, with sumatriptan use reduced to 5 days; acute medication use eventually ceased... This case demonstrates that atogepant (60 mg daily) is an effective and well-tolerated preventive treatment for refractory migraine in MELAS syndrome. Notably, atogepant did not adversely affect the resolution of stroke-like episodes or concurrent L-arginine therapy. Further prospective studies are needed to confirm these findings and establish the role of CGRP antagonists in this population."

Case report • Clinical • CNS Disorders • Depression • Epilepsy • Migraine • Pain